Jazz Pharmaceuticals (NASDAQ:JAZZ) had its price objective raised by Barclays from $205.00 to $225.00 in a report published on Monday, The Fly reports. They currently have an overweight rating on the specialty pharmaceutical company’s stock.
A number of other research analysts also recently weighed in on the company. Royal Bank of Canada raised their price objective on Jazz Pharmaceuticals from $160.00 to $170.00 in a research note on Monday, September 14th. Wolfe Research raised Jazz Pharmaceuticals from a peer perform rating to an outperform rating in a research note on Tuesday, July 28th. The Goldman Sachs Group downgraded Jazz Pharmaceuticals from a neutral rating to a sell rating and set a $128.00 price objective on the stock. in a research note on Monday, September 14th. JPMorgan Chase & Co. started coverage on Jazz Pharmaceuticals in a research note on Monday, September 14th. They issued an overweight rating and a $175.00 price objective on the stock. Finally, Oppenheimer started coverage on Jazz Pharmaceuticals in a research report on Thursday, July 30th. They issued an outperform rating on the stock. Two research analysts have rated the stock with a sell rating, one has given a hold rating and seventeen have issued a buy rating to the company. The stock presently has a consensus rating of Buy and an average price target of $168.53.
Shares of Jazz Pharmaceuticals stock opened at $145.63 on Monday. The firm has a market cap of $8.08 billion, a price-to-earnings ratio of 63.04, a P/E/G ratio of 4.22 and a beta of 1.15. The company has a debt-to-equity ratio of 0.66, a current ratio of 5.62 and a quick ratio of 5.39. Jazz Pharmaceuticals has a 52-week low of $86.88 and a 52-week high of $156.26. The stock has a 50-day simple moving average of $145.01 and a 200-day simple moving average of $122.32.
Jazz Pharmaceuticals (NASDAQ:JAZZ) last announced its quarterly earnings results on Tuesday, August 4th. The specialty pharmaceutical company reported $3.71 earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of $3.11 by $0.60. Jazz Pharmaceuticals had a return on equity of 20.47% and a net margin of 6.01%. The business had revenue of $562.44 million during the quarter, compared to analyst estimates of $503.19 million. During the same period in the previous year, the company earned $4.05 EPS. The firm’s revenue was up 5.3% on a year-over-year basis. As a group, equities research analysts predict that Jazz Pharmaceuticals will post 10.62 earnings per share for the current year.
In related news, CEO Bruce C. Cozadd sold 500 shares of the business’s stock in a transaction on Tuesday, September 1st. The stock was sold at an average price of $134.90, for a total value of $67,450.00. Following the sale, the chief executive officer now owns 336,680 shares of the company’s stock, valued at approximately $45,418,132. The sale was disclosed in a legal filing with the SEC, which is available through this link. Also, CEO Bruce C. Cozadd sold 4,500 shares of the business’s stock in a transaction on Thursday, October 1st. The shares were sold at an average price of $141.94, for a total value of $638,730.00. Following the completion of the sale, the chief executive officer now directly owns 332,180 shares in the company, valued at approximately $47,149,629.20. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 8,363 shares of company stock worth $1,142,374. 4.60% of the stock is currently owned by company insiders.
A number of hedge funds have recently made changes to their positions in JAZZ. AXA boosted its stake in Jazz Pharmaceuticals by 5.5% in the 1st quarter. AXA now owns 161,227 shares of the specialty pharmaceutical company’s stock valued at $16,081,000 after buying an additional 8,461 shares in the last quarter. Advisor Group Holdings Inc. acquired a new stake in shares of Jazz Pharmaceuticals in the first quarter valued at $618,000. APG Asset Management N.V. raised its holdings in shares of Jazz Pharmaceuticals by 43.2% in the first quarter. APG Asset Management N.V. now owns 68,821 shares of the specialty pharmaceutical company’s stock valued at $6,864,000 after buying an additional 20,755 shares during the last quarter. State Street Corp lifted its position in Jazz Pharmaceuticals by 2.5% during the 1st quarter. State Street Corp now owns 1,507,363 shares of the specialty pharmaceutical company’s stock worth $150,344,000 after buying an additional 36,118 shares in the last quarter. Finally, Envestnet Asset Management Inc. grew its holdings in Jazz Pharmaceuticals by 2.9% during the 2nd quarter. Envestnet Asset Management Inc. now owns 84,559 shares of the specialty pharmaceutical company’s stock worth $9,330,000 after acquiring an additional 2,374 shares during the last quarter. 92.82% of the stock is currently owned by institutional investors and hedge funds.
About Jazz Pharmaceuticals
Jazz Pharmaceuticals plc, a biopharmaceutical company, identifies, develops, and commercializes pharmaceutical products for various unmet medical needs in the United States, Europe, and internationally. The company has a portfolio of products and product candidates with a focus in the areas of sleep and hematology/oncology.
Recommended Story: How Short Selling Works
Receive News & Ratings for Jazz Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Jazz Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.